Article in Genes, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed.
Genes · 2025
Article
4 · The record
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors.
Lulu WangDepartments of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Wei WangDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Hannah C BeirdDepartments of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-5078-534X
Xueqian ChengDepartments of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-8454-1071
Hong FangDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Guilin TangDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Gokce A TorunerDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-5305-6337
C Cameron YinDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
M James YouDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Ghayas C IssaDepartments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-4339-8683
Gautam BorthakurDepartments of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Guang PengDepartments of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Joseph D KhouryDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0003-2621-3584
L Jeffrey MedeirosDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0001-6577-8006
Zhenya TangDepartments of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.ORCID 0000-0002-8079-9945
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
In a subset of acute myeloid leukemia (AML) cases, the core binding factor beta subunit gene (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.